Stalevo levodopa/carbidopa/entacapone regulatory update

Orion disclosed in its 2Q13 earnings that Novartis submitted a regulatory application in Japan for Stalevo levodopa/carbidopa/entacapone to treat Parkinson's disease with end-of-dose motor fluctuations not stabilized on levodopa/carbidopa or levodopa/benserazide treatment. The product, which consists of levodopa plus dopa decarboxylase inhibitor and catechol-O-methyl-transferase (COMT) inhibitor, is marketed in the U.S. and EU to treat patients with PD and end-of-dose motor fluctuations not stabilized by levodopa/dopa decarboxylase (DDC) inhibitor treatment. ...